ImmuCell Co. (NASDAQ:ICCC) Sees Large Decline in Short Interest

ImmuCell Co. (NASDAQ:ICCC) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 5,700 shares, a decrease of 12.3% from the June 15th total of 6,500 shares. Based on an average daily trading volume, of 11,700 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.

ImmuCell Price Performance

ImmuCell stock traded up $0.02 during trading hours on Wednesday, reaching $4.29. 4,853 shares of the stock were exchanged, compared to its average volume of 9,330. The company has a market cap of $33.50 million, a P/E ratio of -8.22 and a beta of 0.58. The company has a current ratio of 2.71, a quick ratio of 1.00 and a debt-to-equity ratio of 0.41. ImmuCell has a twelve month low of $4.05 and a twelve month high of $5.87. The stock has a 50 day moving average of $4.51 and a two-hundred day moving average of $4.92.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 15.21% and a negative net margin of 18.31%. The firm had revenue of $7.26 million for the quarter.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Mesirow Financial Investment Management Inc. purchased a new stake in ImmuCell Co. (NASDAQ:ICCC) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell at the end of the most recent quarter. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.